pharmaceutical composition, fusion protein, polynucleotide, vector, isolated cell, methods for producing a fusion protein, for treating or preventing a disease or condition, for diagnosing an individual's susceptibility to developing a disease or condition, for determining suitability of the individual to enter a drug classification experiment, and to identify an agent, use of a combination, and combination.
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
发明人:
ESTHER BANDALA SANCHEZ,JAMES DROMEY,LEONARD CHARLES HARRISON,MARYAM RASHIDI,YUXIA ZHANG
申请号：
BR112014011758
公开号：
BR112014011758A2
申请日:
2012.11.15
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
